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Abstract
Background: Atherosclerosis is an inflammatory condition and increased blood levels of inflammatory biomarkers have
been observed in acute coronary syndromes. In addition, high expression of inflammatory markers is associated with worse
prognosis of coronary artery disease. The presence and extent of inducible ischemia in patients with stable angina has
previously been shown to have strong prognostic value. We hypothesized that evidence of inducible myocardial ischemia
by local lesions, as measured by fractional flow reserve (FFR), is associated with increased levels of blood based
inflammatory biomarkers.
Methods: Whole blood samples of 89 patients with stable angina pectoris and 16 healthy controls were analyzed. The
patients with stable angina pectoris underwent coronary angiography and FFR of all coronary lesions. We analyzed plasma
levels of cytokines IL-6, IL-8 and TNF-a and membrane expression of Toll-like receptor 2 and 4, CD11b, CD62L and CD14 on
monocytes and granulocytes as markers of inflammation. Furthermore, we quantified the severity of hemodynamically
significant coronary artery disease by calculating Functional Syntax Score (FSS), an extension of the Syntax Score.
Results: For the majority of biomarkers, we observed lower levels in the healthy control group compared with patients with
stable angina who underwent coronary catheterization. We found no difference for any of the selected biomarkers
between patients with a positive FFR (#0.75) and negative FFR (.0.80). We observed no relationship between the
investigated biomarkers and FSS.
Conclusion: The presence of local atherosclerotic lesions that result in inducible myocardial ischemia as measured by FFR in
patients with stable coronary artery disease is not associated with increased plasma levels of IL-6, IL-8 and TNF-a or
increased expression of TLR2 and TLR4, CD11b, CD62L and CD14 on circulating leukocytes.
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Introduction
Atherosclerosis is the leading cause of mortality and morbidity
in the Western world and coronary artery disease is its most
prevalent manifestation. Atherosclerosis has been recognized as a
chronic inflammatory disease. The influx of inflammatory cells
into the vascular wall and release of pro-inflammatory substances
drives plaque initiation and progression. In addition, local
inflammation is the key factor in the biological events leading to
plaque rupture and subsequent thrombosis, causing myocardial
infarction and stroke. Ruptured plaques have been shown to be
infiltrated with inflammatory cells [1]. This observation initiated
the search for systemically expressed markers of inflammation that
could reflect the severity and stability of the atherosclerotic disease.
As a result increased levels of pro-inflammatory biomarkers have
been measured in plasma and on blood cells of patients with acute
coronary syndromes [2–4]. Furthermore, higher levels of these
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cytokines have been associated with impaired prognosis in patients
with acute coronary syndromes [5,6].
The detrimental effect of increased inflammatory activity also
applies to stable atherosclerotic disease and even asymptomatic
individuals. In a healthy cohort, increased levels of interleukin (IL)
-6 were associated with increased occurrence of myocardial
infarction and coronary death [7]. In another study, IL-8 was
predictive for the occurrence of cardiovascular events in patients
with stable coronary artery disease [8]. The presence and extent of
inducible ischemia is a strong prognostic factor in stable coronary
artery disease. It has consistently been shown, both invasively and
non-invasively, that coronary artery lesions that give rise to
ischemia negatively affect prognosis. On the other hand, if
coronary stenoses do not cause ischemia, prognosis is excellent
with low event rates [9–12]. It is unknown if the inflammatory
activity in patients at risk is explained by the local functional
severity of a lesion or that it reflects the inflammatory status of the
entire vasculature. Considering the reports that both increased
inflammatory activity and the presence of inducible ischemia affect
the clinical course of stable coronary disease, we hypothesized that
functional parameters of locally inducible ischemia and systemic
inflammatory parameters are related.
Fractional Flow Reserve (FFR) is an invasive, lesion-specific
index of myocardial ischemia and is considered the gold standard
for the assessment of ischemic potential of coronary lesions. FFR
has a well defined cut-off value for ischemic lesions and has shown
excellent reproducibility. FFR-guided treatment of coronary
lesions has been shown to be superior to conventional angiogra-
phy-guided treatment and FFR is of prognostic significance with
respect to future acute myocardial infarction or death [11,12].
In the current study we assessed the relationship of functional
coronary lesion significance, assessed by FFR, with both cell-based
as well as secreted markers of inflammatory activity.
Methods
Patient selection
Our analysis included 89 patients with chronic stable angina
that were presented at the catherization lab of the Catharina
Hospital Eindhoven, the Netherlands. All patients were investi-
gated for ischemia with FFR.
As a negative control group, 16 healthy individuals aged .40
years without known coronary artery disease or atherosclerosis
were included. All participants provided written informed consent
prior to participation. This study was approved by the local ethics
committee. Exclusion criteria were active inflammatory condi-
tions, autoimmune disease, malignancies, use of immunosuppres-
sive drugs and known hematological disorders. Patients with ST-
elevation myocardial infarction were also excluded. Blood of
patients with suspected unstable angina or NSTEMI was studied
but retrospectively excluded from this analysis.
Invasive assessment of ischemia by FFR
The technical aspects of FFR measurement have been
extensively described previously [13]. In short, a stenosis to be
investigated is crossed with a standard pressure-wire (Pressur-
eWiretm Certus, St Jude Medical Inc,USA) through a coronary
guiding catheter after which myocardial hyperemia is induced.
This is achieved by continuous infusion of adenosine 140 mg/kg/
min through a central venous catheter until steady-state maximum
hyperemia is achieved after which pressure proximal (Pa) and
distal to the stenosis (Pd) are measured simultaneously. FFR is
calculated as the ratio of distal coronary pressure divided by
proximal coronary pressure during steady-state maximum hyper-
emia. This procedure is the state-of-the-art operating procedure
for performing FFR.
Patients with inducible myocardial ischemia were defined as
having at least one coronary lesion with an FFR #0.75, while
patients without inducible myocardial ischemia were defined as
having no coronary lesion with an FFR#0.80. These cutoff values
have been extensively validated [14–16]. To clearly demarcate
ischemic status, patients with an intermediate FFR-value (0.76–
0.80) were excluded from the analysis. Chronic total occlusions
were arbitrarily assigned a FFR value of 0.50. In the remainder of
the text patients with at least one FFR-value#0.75 will be referred
to as FFR-positive, while patients with all FFR values .0.80 will
be referred to as FFR-negative.
Coronary angiography was not performed in the healthy
control group. Control subjects were randomly selected from local
laboratory staff and had to meet the following criteria: age above
40, no previous vascular history, no medication use and absence of
inflammatory or autoimmune disease. These subjects were
questioned for coronary risk factors and symptoms of coronary
artery disease. A routine electrocardiogram and standard blood
analysis was performed as described below.
Measurement of systemic markers of inflammation
After inclusion, blood was collected in lithium-heparin (LH) and
ethylenediaminetetraacetic acid (EDTA) anticoagulated tubes. In
the patient group blood samples were drawn immediately before
angiography from the inserted arterial sheath while in healthy
controls blood samples were obtained from a large antecubital
vein.
Standard whole blood analysis, including complete blood cell
count, renal function and lipid spectrum was performed in all
participants.
Cytokine measurements
Portions of 100 ml of whole blood LH – anticoagulated samples
were transferred to 96 wells plates. 100 ml PBS was added and
incubated at 37uC and atmosphere containing 5% CO2 for
2 hours. This was executed to allow valid comparison with the
measurements of cell based parameters obtained with flow
cytometry.
Afterwards, the samples were centrifuged for 5 minutes at
4006g, the supernatant was carefully transferred to sterile tubes
and frozen at 280uC until further analysis. Cytokine levels of
interleukine (IL)-6, IL-8 and tumor necrosis factor (TNF)-a were
measured in these supernatants by Luminex cytometric bead
analysis, according to the manufacturer’s instructions. Undetect-
able values were imputed as 0.1 pg/ml. All levels of cytokines were
corrected for total white blood cell count.
Flow cytometry analysis
To assess expression of surface markers 50 ml of LH-anticoag-
ulated whole blood was incubated with fluorescent antibodies
against TRL2 (CD282 TLR2-FITC, Serotec, UK), TLR4 (CD284
TLR4-RPE, Serotec, UK), CD11b (CD11b PE-Cy7, Becton-
Dickinson, NJ, USA), CD62L (CD62L ECD, Beckman Coulter,
CA, USA) and CD14 (CD14 PC5, Beckman Coulter, CA,USA)
for 30 minutes. After washing and whole blood lysis, the samples
were subsequently analyzed by flow cytometry (Beckman Coulter
FC 500). Granulocytes were gated based on their scatter
properties. Monocytes were identified based on their scatter
properties and positive CD14 staining. Expression of surface
markers was quantified by mean fluorescense intensity (MFI).
Fractional Flow Reserve and Inflammatory Markers
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Severity of ischemic coronary disease and inflammation
To investigate a possible correlation between the severity of
ischemic coronary disease and inflammatory markers we calcu-
lated Functional Syntax Score (FSS) for FFR-positive patients. FSS
is a functional extension of the Syntax Score (a scoring system to
grade anatomical severity of coronary artery disease) which has
been shown to have predictive value in patients with multivessel
disease and left main coronary artery disease treated with either
PCI or CABG [17]. In this scoring system, each lesion is
individually scored on the basis of location and morphological
characteristics. The total score directly reflects the angiographic
extent and severity of coronary artery disease. In a recent study,
FSS showed superior predictive value over SS in FFR-guided PCI
treated cohort [18]. Since all patients in our cohort were treated
with an FFR-guided strategy, this scoring system is appropriate for
this purpose. We hypothesized that increasing severity of the
ischemic coronary disease would be associated with increased
levels of inflammatory markers. To obtain FSS, Syntax score (SS)
was calculated according to the instructions of the web-based
Syntax Score Calculator (www.syntaxscore.com). Next, FSS was
calculated by subtracting the individual scores of lesions with an
FFR.0.80 from the total score. In this way, only hemodynam-
ically significant lesions participate in the total score and thus
reflect the severity of ischemic coronary artery disease (‘‘ischemic
burden’’). The FFS scores of the FFR-positive group were divided
into tertiles. We then compared inflammatory markers of the
individual tertiles of FSS to inflammatory markers measured in the
FFR-negative group and to each other.
Statistical analysis
Results are presented as means6SD or medians (interquartile
range; IQR) in case of a skewed distribution. Continuous variables
were compared between groups with either student’s T, Mann
Whitney U-test in case of comparison between two groups and
ANOVA or Kruskal-Wallis test or Jonckheere-Terpstra for
comparison between multiple groups, as appropriate. Discrete
variables were compared using Chi-square testing. A p val-
ue,0.05 was considered statistically significant. All analysis were
performed using SPSS 17.0 (SPSS inc, Chicago, Ill, USA)
Results
Procedural results
In 108 patients with stable angina, FFR was measured and
inflammatory markers were assessed. Twelve patients with an
intermediate FFR-value (0.76–0.80) were not included in this
analysis. Due to technical errors an additional 7 patients were
excluded from further analysis. Consequently, 89 patients were
analyzed in the current study. Demographics and history of
patients according to ischemic status are presented in Table 1. Of
the patients with an FFR#0.75 included in this analysis 45
patients (76.3%) were treated with PCI, 9 (15.3%) with CABG and
5 (8.5%) treated conservatively. There were no statistically
significant differences in risk profiles between the FFR-positive
and FFR-negative patients, neither in age, sex, risk factors, body
mass index or relevant cardiovascular history. The majority of
patients had a normal Left ventricular ejection fraction (LVEF)
(Table 1). In the healthy control group, 12 (75%) were male with a
mean age of 49.865.6. None of the healthy controls used any
medication. Five healthy control subjects (31.2%) reported a
positive family history and 1 had known hyperlipidemia for which
no medication was taken. None of the control subjects had any
other relevant medical history. BMI of the healthy control subjects
was lower (23.662.0 versus 27.164.3 and 27.663.4, p,0.01).
Medication use in the patient group before undergoing catheter-
ization and FFR-measurement is described in Table 2. Clopido-
grel loading dose was administered depending on whether PCI
was expected to be performed. Use of beta-blockers and
administration of a loading dose clopidogrel was significantly
higher in patients with lowest FFR#0.75 (both p,0.01). Chronic
use of clopidogrel, however, was similar in both groups (p = 0.83).
White blood cell (WBC) count
In the group of patients with stable angina total WBC count,
neutrophil and monocyte-counts did not differ between FFR-
positive and FFR-negative patients, as shown in Table 1. Patients
with stable angina had significantly higher total WBC, neutrophil
and monocyte counts than healthy controls, respectively
6.7261.666109/l versus 5.3761.356109/l leukocytes, p,0.01,
4.3262.236109/l versus 2.9961.116109/l neutrophils, p,0.01
and 0.5660.186109/l versus 0.4360.126109/l monocytes,
p,0.01.
Cytokine concentrations
Concentrations of IL-6, IL-8 and TNF-a were measured in the
supernatants of all patients and healthy controls and corrected for
total white blood cell count. In 2 patients cytokine-concentration
could not be measured, due to technical reasons. Concentrations
Table 1. Baseline Characteristics of patients with stable
angina.
FFR.0.80 FFR#0.75
N=30 N=59 * p-value
Age 63.169.8 60.5610.1 0.24
Sex - n male (%) 20 (66.7) 37 (62.7) 0.71
BMI 27.164.3 27.663.4 0.54
Risk factors- n (%)
Smoking 5 (16.7) 17 (28.8) 0.21
Hypertension 13 (43.3) 27 (45.7) 0.83
DM 6 (20) 14 (23.7) 0.69
Hyperlipidemia 16 (53.3) 28 (47.5) 0.60
Family history 18 (60) 43 (72.9) 0.22
Peripheral artery disease 5 (16.7) 7 (11.8) 0.53
Cerebrovascular disease 1 (3.3) 1 (1.7) 0.62
Previous MI 6 (20) 11 (18.6) 0.88
Previous PCI 13 (43.3) 18 (30.5) 0.23
Previous CABG 1 (3.3) 1 (1.7) 0.62
Renal failure ** 0 (0) 1 (1.6) 0.47
Normal LVEF (if known) 22 (73.3) 42 (71.2) 0.43
Mean lowest FFR 0.8660.05 0.5760.15
White blood cell count (WBC) 6.4961.51 6.8461.73 0.34
Neutrophil count 4.0561.06 4.4662.69 0.43
Monocyte count 0.5460.20 0.5760.16 0.48
Continuous values are presented as means 6 standard deviation (SD). Categorical
values are presented as number (percentages).
*Significance level 0.05. FFR = fractional flow reserve BMI = body mass index
;DM=diabetes mellitus; MI =myocardial infarction; PCI = percutaneous coronary
intervention; CABG= coronary artery bypass grafting; LVEF = left ventricular
ejection fraction.
**Defined as a serum creatinin .150 mmol/l.
doi:10.1371/journal.pone.0046356.t001
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of the above mentioned cytokines were compared among groups.
Results are depicted in Figure 1. We did not observe differences in
concentrations for any of the cytokines in supernatants of FFR-
positive patients compared to those of FFR-negative patients.
Median concentration (IQR) of IL-6 in FFR-positive patients
compared to FFR-negative patients was 0.19 (0.04–0.45) versus
0.09 (0.02–0.54), p = 0.21, concentration of IL-8 was 3.4 (1.9–7.2)
versus 2.7 (1.8–6.9), p = 0.56 and concentration of TNF-a 0.30
(0.10–0.75) versus 0.34 (0.14–0.66), p = 0.94. We did observe a
significantly lower concentration of both IL-6 and TNF-a in the
healthy controls compared to the patients with stable angina
(p = 0.001 and p= 0.03, respectively).
Concentration of IL-8 in the supernatants did not significantly
differ between all three groups (p = 0.21).
Expressions of TLR2, TLR4, CD14, CD11b and CD62L on
peripheral blood cells
Expression of TLR2 and TLR4 quantified by mean fluores-
cence intensity (MFI), was measured by flow cytometry on
monocytes and granulocytes in blood samples of all 89 patients.
We did not observe any significant differences between the
expression levels for TLR2 and TLR4 on both monocytes
(Figure 2A) and granulocytes (Figure 2B) between FFR-positive
and FFR-negative patients. TLR2 and TLR4 expression on
monocytes and TLR4 expression on granulocytes in healthy
control subjects was significantly lower compared to both FFR-
positive and FFR-negative patients (p,0.01, p = 0.01 and
p= 0.03).
We then compared expression levels of CD11b and CD62L on
both monocytes and granulocytes and CD14 on monocytes
(Figure 3A and 3B). We observed no differences between the
FFR-groups in expression of CD11b on monocytes (p = 0.34) or
granulocytes (p = 0.85). Expression of CD62L on both monocytes
and granulocytes also did not differ between FFR-positive and
FFR-negative patients (p = 0.86 and p= 0.64, respectively).
Healthy control subjects had significantly lower expression levels
of CD11b on monocytes (p,0.01) and CD62L on granulocytes
(p = 0.04). CD11b on granulocytes and CD62L on monocytes did
not differ between groups (p = 0.95 and p= 0.43 respectively).
Moreover, no difference in expression of CD14 on monocytes
could be detected (p = 0.92).
Influence of severity of ischemic coronary disease on
inflammatory markers
To assess the influence of the severity and extent of ischemic coronary
disease on the measured markers of inflammation we calculated
FSS for each FFR-positive patient (as described above), divided
FSS-scores into tertiles (range 1 to 28, intertertile range 7 to 14)
and compared inflammatory markers of each tertile to each other
and to FFR-negative patients. No between-subgroup differences
were noted (p-values all .0.05). More importantly, there was no
incremental relation between FSS tertiles and the measured
markers (Figure 4A–C).
Discussion
The presence of inducible myocardial ischemia is of key
importance for the prognosis of stable coronary artery disease.
Numerous studies have shown increased rates of myocardial
infarction and cardiovascular death when substantial myocardial
ischemia is present as measured by FFR. Systemically measured
inflammatory markers have also been associated with adverse
outcome in patients suffering from cardiovascular disease. The
origin of these inflammatory parameters can be the local
inflammatory unstable plaque, can be a reflection of the
atherosclerotic burden in the vascular system or an epi-phenom-
enon. Since plasma levels of pro-inflammatory cytokines as well as
cell-based markers on circulating cells have been found to be
elevated in acute coronary syndromes, and the presence and
Table 2. Medication use of patients with stable angina at
inclusion.
FFR.0.80 FFR#0.75
Medication – n(%) N=30 N=59 p-value*
ASA 24 (80) 55 (93) 0.08
b-blocker 18 (60) 51 (86) ,0.01
ACE-inhibitor 8 (26.7) 15 (25.4) 0.90
Statin 28 (93.3) 54 (91.5) 0.77
Clopidogrel (chronic use) 9 (30) 19 (32.2) 0.83
Clopidogrel (loading dose) 3 (10) 32 (54.2) ,0.01
Proportions were compared using Chi-square testing.
*Significance level 0.05. FFR = fractional flow reserve; ASA = Acetylsalicylic acid;
ACE = angiotensin-converting enzyme.
doi:10.1371/journal.pone.0046356.t002
Figure 1. Comparison of levels of cytokines for FFR-positive and FFR-negative patients and healthy controls. *Comparison by Kruskal-
Wallis test.** Between subgroup differences compared with Mann Whitney U test.
doi:10.1371/journal.pone.0046356.g001
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extent of inducible ischemia associated with increased occurrence
of myocardial infarction and death, we hypothesized that
inducible ischemia is associated with increased levels of blood
derived inflammatory markers.
In this study, however, we found no relation between the
investigated inflammatory markers and the presence of inducible
myocardial ischemia as evidenced by FFR. In line with previous
reports, we observed a difference in inflammatory markers
between healthy subjects and patients with stable angina, pointing
to a chronically elevated inflammatory status in patients with
coronary artery disease [19]. Our observations suggest that this
elevated inflammatory state is not altered by the presence of
inducible ischemia by local atherosclerotic luminal narrowing, but
probably a reflection of co-morbidities or systemic risk factors with
concomitant generalized atherosclerotic disease, independently of
its functional severity.
The latter is supported by the baseline characteristics that reveal
that the FFR-positive and negative patient groups have compa-
rable atherosclerotic risk profiles and history of previous MI or
PCI as opposed to the healthy control group, which has virtually
no risk factors and no history of coronary pathology. This study
therefore shows that local lesions that may induce local ischemia
do not explain the increased inflammatory blood profile in patients
suffering from stable coronary artery disease. Even if the extent
and severity of ischemic coronary disease is taken into account
according to FSS, no relationship between the inflammatory
markers and inducible ischemia could be identified.
Fractional Flow Reserve (FFR) is the most reliable method for
assessing the ischemic potential of coronary stenoses. Reducing
myocardial ischemia is associated with improved prognosis [20]
and by use of FFR it is possible to adequately pinpoint which
lesions are responsible for ischemia. FFR-guided revascularization
provides optimal relief of ischemia, preventing unnecessary
stenting or bypass surgery of non-ischemia causing lesions while
at the same time preventing undertreatment of lesions that appear
moderate on angiography but do cause ischemia [21].
In this study, we investigated a specific subset of inflammation
markers known to be associated with coronary artery disease. Toll-
like receptors (TLRs) are a key part of the innate immune system
and have been shown to play an important role in both the
initiation and progression of coronary disease [22,23]. Increased
expression of TLR4 on circulating monocytes and increased
transcription of pro-inflammatory cytokines and co-stimulatory
molecules, reflecting downstream activation of TLR stimulation,
have been found in patients with unstable angina (UA) and acute
myocardial infarction (AMI) compared to patients with stable
angina and healthy controls [24,25].
Figure 2. Expression levels of TLR2 and TLR4 on monocytes (A) and granulocytes (B) FFR-positive and FFR-negative patients and
healthy control subjects. *Comparison by Kruskal-Wallis test for all groups.** Between subgroups with Mann Whitney U test. TLR = toll-like
receptor.
doi:10.1371/journal.pone.0046356.g002
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CD11b, also known as Integrin aM, is involved in adhesion and
transendothelial migration an early marker for cellular activation
of leukocytes [26]. Furthermore, CD11b-expression has been
shown to be upregulated immediately after stimulation of TLRs
[27]. CD62L (L-selectin) is a member of the selectin family,
expressed on both monocytes and granulocytes and is involved in
cell adhesion [28]. Both granulocytes and monocytes readily shed
CD62L upon stimulation.
It has been shown in both experimental and clinical settings that
short lasting myocardial ischemia elicits an inflammatory response.
In a porcine experiment 30 minutes of induced ischemia resulted
in marked increase of plasma levels of IL-6 and TNF-a [29]. In
patients with coronary artery disease, dobutamine-induced ische-
mia resulted in an increase in plasma levels of IL-6 and tissue
factor. Furthermore, IL-6 levels were related to left ventricular
dysfunction at peak stress and rate of recovery of left ventricular
function [30]. In patients with a reversible perfusion defect in
myocardial perfusion imaging after stress, TLR mediated leuko-
cyte activation was attenuated [31]. These findings provide both
experimental as well as clinical evidence that an acute inflamma-
tory response to ischemic episodes occurs which is detectable in
peripheral blood samples. However, these results pertain to acutely
induced ischemia and it is unknown whether inflammatory status
is permanently altered by short repetitive ischemic episodes. In this
study we found no evidence for this.
Limitations
Due to the fact that FFR measurements are obviously unknown
prior to angiography, patient groups are inevitably unequal in size.
Also, FFR-positive patients were more frequently pre-treated with
a loading dose of clopidogrel. Clopidogrel has been shown to have
anti-inflammatory properties [32], and thus it is possible that
inflammatory status in the FFR-positive group could be underes-
timated by pre-treatment. It must be noted however, that any anti-
inflammatory properties of clopidogrel have mainly been observed
during chronic treatment [32–35], and chronic clopidogrel
treatment did not differ between the FFR positive and negative
groups. Quinn et al specifically investigated effects of clopidogrel
treatment (.24 hours) before PCI on inflammatory markers and
observed that serum CD40 ligand and IL-6 were not affected by
clopidogrel pre-treatment [36]. It is therefore unlikely that pre-
treatment with a loading dose of clopidogrel would have played a
significant role in our study. In any case, we feel withholding
clopidogrel pretreatment in patients if stenting is anticipated is
unethical and potentially hazardous. Over 90% of the patients
with stable angina in this study are treated with statins (HMG-
CoA reductase inhibitors), which have been shown to have anti-
inflammatory properties [37–39]. Despite the use of statins,
inflammatory markers are increased in the patient groups as
compared to the healthy controls. In the patient groups it is
conceivable that use of statins may mask small differences related
to the presence or absence of inducible ischemia. Blood samples
were taken from an arterial sheath in the patient groups.
Figure 3. Expression levels of CD11b, CD62L and CD14 on monocytes (A) and CD11b and CD62L on granulocytes (B) in FFR-
negative patients, FFR-positive and healthy control subjects. *Comparison by Kruskal-Wallis test for all groups.** Between subgroups with
Mann Whitney U test.
doi:10.1371/journal.pone.0046356.g003
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Consequently, no statements can be made on possible differences
in other locations of the vascular system (e.g. coronary artery or
coronary sinus) in these patients. In the healthy control group,
blood was obtained from an antecubital vein. Although differences
in inflammatory markers between locally (coronary sinus) obtained
blood and peripheral blood in coronary artery disease have been
observed [40,41], to our knowledge differences of these markers
between peripheral venous and peripheral arterial blood have not
been reported [42]. BMI of the healthy control subjects was
significantly lower than that of the patient groups. As increased
levels of inflammatory markers have been reported in obese
subjects [43–45], we cannot exclude the possibility that this may
Figure 4. Concentrations of cytokines and surface markers on monocytes and granulocytes according to FSS tertiles and FFR-
negative patients. Concentrations of cytokines (A) and surface markers on monocytes (B) and granulocytes (C) according to FSS tertiles (of FFR-
positive patients) and FFR-negative patients. Comparison of all subgroups was performed with the Jonckheere-Terpstra test. FSS = functional syntax
score.
doi:10.1371/journal.pone.0046356.g004
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have influenced biomarker levels in the patient groups, although
BMI was only moderately increased in the FFR positive and FFR-
negative patients. In this study we only analyzed a specific subset
of inflammatory markers; IL-6, IL-8 and TNF-a as inflammatory
cytokines and CD11b, CD62L, TLR2 and TLR4 as markers for
cellular activation of circulating cells. Although we investigated cell
based expression as well as secreted markers for inflammation, we
cannot discount the possibility that repetitive ischemia exerts
effects through different mechanisms and is reflected by different
biomarkers than the ones investigated here.
Conclusions
Inducible myocardial ischemia is not associated with increased
concentrations of IL-6, IL-8 and TNF-a in blood or expression of
CD11b, CD62L, CD14, TLR2 or TLR4 on circulating leukocytes
in patients with stable angina.
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